NanoSphere Health Sciences Inc (NSHS) AI Stock Analysis

• Market Cap: C$205.50K
• Dividend Yield: N/A
• Average Volume (3M): 9.76K
• Price to Earnings (P/E): ―
• Beta (1Y): -3.79
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 10,275,205
• 10 Day Avg. Volume: 800
• 30 Day Avg. Volume: 9,759
• PEG Ratio: 0.00
• Price to Book (P/B): -0.26
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.95
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: C$0.03 ▲(50.00% Upside)
• Action: Upgraded Date: 01/27/26
• Date: Action: Upgraded 01/27/26

The score is primarily constrained by very weak financial performance—no recent revenue and deeply negative equity—despite improving loss and cash-burn trends. Technicals provide some support from short-term momentum, while valuation looks inexpensive on P/E but is less reliable given the underlying fundamentals.

Positive Factors

Improving cash burn

Material reduction in cash outflows demonstrates tighter cash management and a smaller recurring funding gap. Over the coming months this improves operational runway, lowers near-term financing pressure, and gives management more time to execute strategic initiatives or secure partnerships.

Operating losses narrowed

Steady compression of operating losses reflects durable cost discipline and a structural move toward break-even economics. If sustained, narrower losses reduce ongoing cash needs, improve credibility with investors/partners, and increase the chance of reaching commercial viability without acute dilution.

Modest absolute debt

Low nominal debt keeps fixed financing obligations minimal, limiting interest burden and default risk. This structural low leverage provides flexibility for restructuring, negotiating non-dilutive funding, or absorbing short-term shocks while management pursues revenue generation or strategic transactions.

Negative Factors

No commercial revenue

Absence of revenue indicates no proven commercial product or market traction, creating fundamental uncertainty about scalable cash generation. Without demonstrated sales, the business model remains unproven, making long-term funding and sustainable operations dependent on future execution or external support.

Deep negative shareholders' equity

Persistently negative equity signals solvency and capitalization issues, constraining access to traditional debt and signaling creditor or investor concern. Structurally this raises the probability of dilution, restructuring, or more expensive financing that can impair long-term shareholder value and strategic flexibility.

Ongoing negative cash flow

Consistent negative operating and free cash flow means the company structurally depends on external financing to sustain operations. Over 2–6 months this increases dilution and execution risk, and raises concern about the firm’s ability to fund development or commercialization without clear revenue sources.

NanoSphere Health Sciences Inc Business Overview & Revenue Model

Company Description

NanoSphere Health Sciences Inc., a nano-biotechnology company, focuses on providing biologically active compounds in the United States and Canada. It offers NanoSphere Deliver System, a platform using nanotechnology in the bio delivery of supplements, nutraceuticals, and over-the-counter medications for the cannabis, pharmaceutical, and animal health industries. The company was incorporated in 2005 and is headquartered in Vancouver, Canada.

How the Company Makes Money

NanoSphere Health Sciences Inc makes money primarily through the commercialization and licensing of its NanoSphere Delivery System technology. The company generates revenue by partnering with nutraceutical and pharmaceutical companies to integrate its delivery system into their products, thereby enhancing their value proposition. Additionally, NanoSphere Health Sciences may earn revenue from direct sales of products developed using its technology, as well as through strategic partnerships and collaborations that provide access to new markets and revenue streams. Key factors contributing to its earnings include the effectiveness of its technology, the ability to secure partnerships with industry leaders, and the expansion of its product portfolio.

NanoSphere Health Sciences Inc Financial Statement Overview

Summary

Financial profile remains highly speculative: revenue has been effectively $0 across recent years and losses persist. Cash burn has improved materially and operating losses have narrowed, but stockholders’ equity is deeply negative, indicating elevated solvency/financing risk.

Income Statement

The company has effectively no revenue in recent years (2020–2024 annual reports show $0 revenue), indicating a lack of commercial scale. Losses persist, though the operating loss has narrowed materially over time (from roughly -$3.24M in 2019 to about -$0.22M in 2023 and approximately -$0.0002M in 2024), suggesting cost reduction. Profitability remains weak with ongoing negative earnings and no demonstrated margin structure in the latest periods due to zero revenue.

Balance Sheet

The balance sheet is highly stressed, with stockholders’ equity deeply negative across all periods (about -$1.22M in 2024 versus -$1.56M in 2023), which is a major solvency and financing risk. Total assets are very small and have trended down sharply from 2021, limiting financial flexibility. Debt is modest in absolute terms (about $30.7K in 2024), but negative equity makes leverage indicators difficult to interpret and still highlights a weak capital structure.

Cash Flow

Cash burn continues: operating cash flow and free cash flow are negative every year shown. That said, cash outflow has improved significantly versus prior years (about -$35.9K in 2024 vs -$53.7K in 2023 and far better than 2019’s roughly -$1.08M), indicating tighter cash management. Free cash flow improved year over year in 2024, but the business still relies on external funding unless revenue ramps meaningfully.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	244.44K	0.00	0.00	-286.00K	-341.00K	-529.77K
Net Income	285.05K	―	-228.13K	-282.00K	-356.00K	-591.22K
Balance Sheet
Total Assets	16.21K	13.59K	17.97K	60.05K	132.51K	55.19K
Cash, Cash Equivalents and Short-Term Investments	2.49K	2.02K	9.32K	55.01K	130.76K	12.95K
Total Debt	45.41K	30.71K	0.00	0.00	0.00	73.73K
Total Liabilities	1.39M	1.23M	1.57M	1.37M	1.21M	1.51M
Stockholders Equity	-1.37M	-1.22M	-1.56M	-1.31M	-1.08M	-1.45M
Cash Flow
Free Cash Flow	-6.91K	-35.92K	-53.70K	-67.66K	-64.68K	-47.26K
Operating Cash Flow	-6.90K	-35.92K	-53.70K	-67.66K	-64.68K	-47.26K
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	13.70K	28.83K	0.00	0.00	182.43K	34.27K

NanoSphere Health Sciences Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NSHS, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 15.40 is Positive, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:NSHS.

NanoSphere Health Sciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NSHS	48 Neutral	C$205.50K	-5.88	8.55%	―	―	―
VXL	43 Neutral	C$617.52K	-6.34	-10.30%	―	―	46.32%
CHGX	24 Underperform	C$415.65K	-0.53	21.10%	―	―	―
WBIO	22 Underperform	C$324.76K	-38.89	1.08%	―	―	―